Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Noom is the latest digital health company to jump into the off-label weight loss drug market to make medications more ...

Following a monthslong battle over CEO Anne Wojcicki’s plans to take 23andMe private, all seven independent members of its ...

Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has ... drug is administered orally – which makes it easier to take than Novo Nordisk’s Wegovy and Eli ...

If you guessed weight loss, you are right on the money. Therapies in this field, such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy, are generating mouthwatering sales, so it's no wonder other ...

Company earnings reported early in the quarter showed growth remained strong, with improved manufacturing volumes and steady ...

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

A first-of-its-kind analysis conducted as part of an investigation by journalists in eight countries found that some of the ...

However, the analysts said: “Given our own forecast that CPI inflation will rise back to 2.9pc by January next year (perhaps ...

The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, infusion, dropper a ...

Viking Therapeutics Inc. (NASDAQ: VKTX), a clinical-stage biotechnology company with a market cap approaching $7 billion, is ...